USD 2.46 billion
Report ID: SQSG35I2014 | Region: Global | Published Date: October, 2022 | Pages: 157 | Tables: 66 | Figures: 65
Global Hyperphosphatemia Therapeutics Market was valued at USD 2.46 billion in 2021,and it is expected to reach USD 3.53 billion by 2028 at a CAGR of 5.3 % over the forecast period (2022-2028).
Hyperphosphatemia occurs when the blood contains an excessive amount of phosphate. This condition occurs in almost 90% of end-stage renal disease patients going through dialysis. Hyperphosphatemia therapeutics such as phosphate binders are used to reduce the gastrointestinal absorption of phosphorus. The most commonly prescribed phosphate binders are calcium salts, but these may produce hypercalcemia. Similarly, there are several phosphate binder drug classes used such as sevelamer, lanthanum carbonate, magnesium-based phosphate binders, and iron-based phosphate binders. The population with chronic kidney disease and cardiovascular disorders tends to have an abnormally high level of phosphate. Hyperphosphatemia is a significant cause of mortality and morbidity in people with chronic renal disorders. The kidney's failure to eliminate phosphate is the most frequent reason for rising phosphate levels. Numerous hyperphosphatemia therapy approaches have been researched and investigated to lessen the burden of the condition. To control and prevent hyperphosphatemia, numerous phosphate-lowering hyperphosphatemia therapy strategies have been used. Hyperphosphatemia is irregularly caused by a large transcellular movement of phosphate into the extracellular space, overwhelming the renal excretory capacity. Such transcellular movement frequently takes place in diabetic ketoacidosis, nontraumatic rhabdomyolysis, crush injuries, overwhelming systemic infections, tumor lysis syndrome. Hyperphosphatemia may also take place due to excessive oral phosphate administration, and, at times, with overuse of enemas carrying phosphate.
Additionally, rising incidence rates of hyperphosphatemia and rising demand for effective hyperphosphatemia treatment alternatives are the main drivers of the Market. For dialysis patients, maintaining an ideal phosphate level can be quite difficult. And occasionally, phosphate is completely removed from the body during dialysis, in which case patients must take phosphate binders to keep their phosphate levels stable. This might limit the global hyperphosphatemia therapeutics market growth.
Global Market Size
USD 2.46 billion
To get more reports on the above market click here to Buy The Report
The Global Hyperphosphatemia Therapeutics Market is segmented by Product Type, Distribution Channel, and Region. Based on Product Type, the market is segmented into Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, and Others. Based on Distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.
Analysis by Product Type
Based on Product Type, the market is segmented into Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, and Others. The sevelamer segment of the market held a significant share in the market in 2021. A shift in healthcare providers' choices away from calcium-based phosphate binders due to these products' drawbacks, including higher pill burden, risk of cardiovascular complications, and relatively lower absorption in elderly patients, is largely responsible for the increased demand for sevelamer-based phosphate binders in developed and underdeveloped economies.
Further, there has also been an increased demand for iron-based phosphate binders among medical professionals due to the lack of study on the long-term safety profile of sevelamer and other unique benefits of iron-based drugs. Along with the development of new generic and branded pharmaceuticals in this class by key players, this is boosting the availability of these medications in both developed and developing countries.
Analysis by Distribution Channel
Based on the distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market with the highest share in 2021. This is attributed to sizable patient populations seeking dialysis treatment in medical facilities around the world. Additionally, rising economies with high treatment costs, like India, have seen a large increase in the number of dialysis patients in these countries. Consequently, segmental growth will be supported by a large number of patients using hospital facilities. Further, during the projection period, the online pharmacies segment is anticipated to expand at the fastest CAGR. The shift of the patient population toward e-commerce platforms for the purchase of medications for the treatment of hyperphosphatemia in major cities is the major aspect of this segmental growth.
To get detailed analysis on other segments, Request For Sample Report
The Global Hyperphosphatemia Therapeutics Market is segmented based on geography as North America, Europe, Asia-Pacific, Latin America, and MEA. Among these regions, the North American region held a significant share in the market, which is followed by Europe, Asia Pacific, Latin America, the Middle East, and Africa. The dominance of North America can be attributed in terms of income, North America is by far the market leader for medications for hyperphosphatemia worldwide. The rising prevalence of diabetes and osteoporosis as well as many chronic renal diseases are driving the market for hyperphosphatemia therapeutics in North America. The market is expanding at the fastest rate in Asia-Pacific. In terms of income and size, China is anticipated to be the Asia-Pacific region's largest market. It is anticipated that demand for hyperphosphatemia medications in China will be fuelled by the increasing healthcare infrastructure across the nation, spurred by the country's central government's robust growth initiatives.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report
The Global Hyperphosphatemia Therapeutics Market is highly fragmented due to the strong presence of a large number of players. As a result, the global Hyperphosphatemia Therapeutics market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology.
Top Player's Company Profiles
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our business information services team that collects, collates, co-relates, and analyses the data collected by means of primary exploratory research backed by the robust secondary desk research.
According to our analysis, based on the region, the North American region dominated the global hyperphosphatemia therapeutics market over other regions. The dominance of North America can be attributed to increased income levels, the region by far being the market leader for medications for hyperphosphatemia, along with the advanced healthcare infrastructure. On the other hand, based on the segmentation, the Sevelamer-based phosphate binders segment held the most dominating share in the market attributing to the increasing prevalence of chronic and renal diseases across the globe.
|Market size value in 2021,and||USD 2.46 billion|
|Market size value in 2028||USD 3.53 billion|
|Forecast Unit (Value)||USD Billion|
|Regions covered||North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)|
Free report customization with purchase. Customization includes:-
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Parent Market Analysis
KEY MARKET INSIGHTS
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Hyperphosphatemia Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Hyperphosphatemia Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Hyperphosphatemia Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Hyperphosphatemia Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.SPEAK TO AN ANALYST
Get lifetime access to our reportsBasic Plan $5,000 Team Plan $10,000 SUBSCRIBE NOW
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.
Product ID: SQSG35I2014